Aprepitantbehandling ophørte på grund af bivirkninger hos 1, 1% af patienterne i behandling med aprepitantregime sammenlignet med 0, 5% af patienterne i standardbehandling.
Aprepitant was discontinued due to adverse reactions in 1.1% of patients treated with the aprepitant regimen compared with 0.5% of patients treated with standard therapy.